Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001268 | 0.81 | HRH4 (0.39) | NOS2KCNH2CD274LMNAAPEX1 | |
| SCHEMBL21099036 | 0.78 | HRH4 (0.44) | NOS2NAMPTKCNH2CD274LMNA | |
| SCHEMBL10233970 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL28600173 | 0.75 | LMNA (0.43) | NOS2NAMPTKCNH2CD274LMNA | |
| SCHEMBL12697598 | 0.73 | — | — | |
| SCHEMBL20233602 | 0.73 | NAMPT (0.48) | NOS2NAMPT | |
| SCHEMBL24493159 | 0.72 | — | — | |
| SCHEMBL4762505 | 0.72 | NOS2 (0.42) | NOS2NAMPTKCNH2LMNAAPEX1 | |
| SCHEMBL27414689 | 0.72 | NOS2 (0.46) | NOS2NAMPTKCNH2LMNAAPEX1 | |
| Hydrochloric Acid SCHEMBL28771025 | 0.71 | CYP3A4 (0.41) | NOS2NAMPTKCNH2LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | BioVersys AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | MELINTA THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065966-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | NOS2 188/4885NAMPT 542/4885KCNH2 3959/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | NOS2 1135/4885NAMPT 3524/4885KCNH2 3044/4885 |
| US-10947237-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | NOS2 188/4885NAMPT 542/4885KCNH2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.